Difference in serotonergic and noradrenergic regulation of human social behaviours.

Versiani M, Cassano G, Perugi G, 
Benedetti A, Mastalli L, Nardi A, Savino M
Institute of Psychiatry, 
Federal University of Rio de Janeiro, Brazil.
J Clin Psychiatry 2002 Jan;63(1):31-7

ABSTRACT

BACKGROUND: Tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) as well as benzodiazepines have been shown to be effective for the treatment of panic disorder. The introduction of SSRIs has enabled a greater understanding of the role of serotonin in the etiology of panic disorder; however, the role of norepinephrine has been more challenging to ascertain. The aim of this study was to determine the efficacy and tolerability of reboxetine, a novel selective norepinephrine reuptake inhibitor, in patients with panic disorder with and without agoraphobia. 

METHOD: Eighty-two patients (aged 18-65 years) with DSM-III-R panic disorder, with or without agoraphobia, were randomly assigned to receive 6 to 8 mg/day of reboxetine (42 patients) or placebo (40 patients) for 8 weeks in this placebo-controlled, parallel-group, double-blind clinical trial. 

RESULTS: Of the 82 patients enrolled in the trial, 75 were considered in the analysis (37 patients in the reboxetine group and 38 patients in the placebo group). At last assessment, there was a significant reduction in the mean number of panic attacks (range, 9.3-1.2) and phobic symptoms (range, 8.1-3.2) in the reboxetine group compared with the placebo group (ranges, 8.5-5.8 and 7.7-5.2, respectively; p < .05). Improvement in Hamilton Rating Scale for Depression, Hopkins Symptom Checklist-90, and Sheehan Disability Scale scores were also greater in the reboxetine group compared with the placebo group. Adverse events reported more frequently with reboxetine than placebo included dry mouth (36% vs. 16%), constipation (27% vs. 22%), and insomnia (26% vs. 22%). 

CONCLUSION: Reboxetine was effective and well tolerated in the treatment of panic disorder.

Tianeptine | Moclobemide | Picamilon | cataract | stroke | diabetes
Home | Order
    www.AlzheimersTreatments.com

                    Reboxetine  research / abstracts

  1.  Reboxetine  role in antidepressant therapy
  2.  Reboxetine  efficacy and tolerability
  3.  Reboxetine  clinical pharmacologic profile
  4.  Reboxetine  Inhibiting noradrenaline and serotonin reuptake 
  5.  Reboxetine  and depression in the elderly
  6.  Reboxetine  with severe major depressive disorder
  7.  Reboxetine  clinical efficacy in major depression
  8.  Reboxetine  tolerability and safety for major depression
  9.  Reboxetine  comparison with fluoxetine
 10. Reboxetine  versus fluoxetine, impact on social functioning
 11. Reboxetine  versus fluoxetine, differential effects
 12. Reboxetine  prevents relapse in  major depression
 13. Reboxetine  efficacy compared with imipramine
 14. Noradrenaline reuptake inhibition
 15. Antidepressants  noradrenergic versus serotonergic
 16. Reboxetine  in the treatment of bulimia
 17. Reboxetine  hemodynamic effects in healthy males
 18. Reboxetine  effects of antidepressant therapy
 19. Reboxetine  place in antidepressant therapy
 20. Reboxetine  stimulant effects in patients with narcolepsy
 21. Reboxetine  selective noradrenaline reuptake inhibitor (NARI)

  Reboxetine  manufacturer's product insert                   

Galantamine | Memantine | Vinpocetine | Idebenone | Pyritinol | cataract
Picamilon | Modafinil | Deprenyl | Piracetam | stroke | benfotiamine

HOME                          to order

 

Hit Counter